Clinical characteristics and outcomes of the multisystem inflammatory syndrome in children (MIS-C) following COVID-19 infection in Iran: A multicenter study

Objectives This study aimed to assess the clinical characteristics, treatment and outcomes of the multisystem inflammatory syndrome in children (MIS-C) following COVID-19 in five different geographical regions of Iran. Methods In this multicenter observational study, patients <21 years were included between March 2020 and October 2021. By Disease Control and Prevention (CDC) checklist, demographic characteristics, comorbidities, clinical signs and symptoms, laboratory and radiology findings, and treatment were collected. Statistical analysis was using Chi-square and t-test in STATA14. Results In total 225 patients with median age of 55 (26–96) months were included that 59.56% boys. 57.33% were admitted to the PICU with a median of 7 days (4–10). 95.56% of patients were discharged with recovery and the rest died. All of the patients in our study were included based on the MIS-C criteria. However, some patients had Kawasaki symptoms, so we compared the clinical and epidemiological characteristics of the two groups. Conjunctival injection, cervical lymphadenopathy>1.5 cm diameter, and strawberry tongue in Kawasaki-like MIS-C patients were higher than of MIS-C patients, and this difference was significant(p<0.001). The most common comorbidity was obesity (24.86%). Most patients tested for COVID-19 and about 60% of the patients had a positive test by serology or reverse transcription-polymerase chain reaction (RT-PCR). Gastrointestinal (88.89%) and hematologic signs (84.44%) were most common. Most drugs used in patients were IVIG and steroids. 88.07% and 61.29% of the patients had at least one problem in echocardiography and lung CT, respectively. Conclusions The best outcome was seen in patients who were treated with both IVIG and steroids on the first days of admission. Myocarditis was common in two groups of patients. According to most patients had echocardiography abnormal, screening of heart function is recommended for patients.

[1]  D. Singh-Grewal,et al.  Multisystem inflammatory syndrome in children and Kawasaki disease: a critical comparison , 2021, Nature Reviews Rheumatology.

[2]  E. Wu,et al.  Cardiac Manifestations of Multisystem Inflammatory Syndrome in Children (MIS-C) Following COVID-19 , 2021, Current Cardiology Reports.

[3]  M. Oster,et al.  Demographic and Clinical Factors Associated With Death Among Persons <21 Years Old With Multisystem Inflammatory Syndrome in Children—United States, February 2020–March 2021 , 2021, Open forum infectious diseases.

[4]  P. Hashkes,et al.  Characterizing the differences between multisystem inflammatory syndrome in children and Kawasaki disease , 2021, Scientific Reports.

[5]  David A. Williams,et al.  Mechanisms underlying genetic susceptibility to multisystem inflammatory syndrome in children (MIS-C) , 2021, Journal of Allergy and Clinical Immunology.

[6]  A. Bhutta,et al.  Multisystem inflammatory syndrome (MIS-C) in Pakistani children: A description of the phenotypes and comparison with historical cohorts of children with Kawasaki disease and myocarditis , 2021, PloS one.

[7]  Manish M Patel,et al.  Incidence of Multisystem Inflammatory Syndrome in Children Among US Persons Infected With SARS-CoV-2 , 2021, JAMA network open.

[8]  A. Orgun,et al.  Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with COVID-19: A Case Series Experience in a Tertiary Care Hospital of Southern Turkey , 2021, Journal of tropical pediatrics.

[9]  Jun-bao Du,et al.  Similarities and differences between multiple inflammatory syndrome in children associated with COVID-19 and Kawasaki disease: clinical presentations, diagnosis, and treatment , 2021, World Journal of Pediatrics.

[10]  J. Merckx,et al.  Multicenter cohort study of multisystem inflammatory syndrome in children (MIS-C) , 2021, medRxiv.

[11]  Resul Yılmaz,et al.  Clinical features and outcome of MIS-C patients: an experience from Central Anatolia , 2021, Clinical Rheumatology.

[12]  M. Qorbani,et al.  Characteristics of Children With Kawasaki Disease-Like Signs in COVID-19 Pandemic: A Systematic Review , 2021, Frontiers in Pediatrics.

[13]  M. Oster,et al.  Factors linked to severe outcomes in multisystem inflammatory syndrome in children (MIS-C) in the USA: a retrospective surveillance study , 2021, The Lancet Child & Adolescent Health.

[14]  Iqbal Bano,et al.  Is leukopenia and lymphopenia a characteristic feature of COVID-19 in children? , 2021, Pakistan journal of medical sciences.

[15]  Soo-Young Lee,et al.  Clinical features, diagnosis, and outcomes of multisystem inflammatory syndrome in children associated with coronavirus disease 2019 , 2020, Clinical and experimental pediatrics.

[16]  F. Hassani,et al.  COVID-19 and multiorgan failure: A narrative review on potential mechanisms , 2020, Journal of Molecular Histology.

[17]  Seema Sharma,et al.  A Systematic Review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 Infection. , 2020, The Pediatric infectious disease journal.

[18]  Álvaro Freitas Moreira,et al.  Multisystem inflammatory syndrome in children: A systematic review , 2020, EClinicalMedicine.

[19]  V. Ziaee,et al.  Multisystem inflammatory syndrome associated with SARS-CoV-2 infection in 45 children: a first report from Iran , 2020, Epidemiology and Infection.

[20]  J. Newburger,et al.  Cardiac manifestations in SARS-CoV-2-associated multisystem inflammatory syndrome in children: a comprehensive review and proposed clinical approach , 2020, European Journal of Pediatrics.

[21]  Edward Y Lee,et al.  Imaging Findings in Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with COVID. , 2020, AJR. American journal of roentgenology.

[22]  Zhe Luo,et al.  D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study , 2020, Journal of Intensive Care.

[23]  Simon Li,et al.  Multisystem Inflammatory Syndrome in U.S. Children and Adolescents , 2020, The New England journal of medicine.

[24]  P. Davies,et al.  Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2. , 2020, JAMA.

[25]  Hongzhou Lu,et al.  Analysis of coagulation parameters in patients with COVID-19 in Shanghai, China. , 2020, Bioscience trends.

[26]  S. Maskatia,et al.  COVID-19 and Kawasaki Disease: Novel Virus and Novel Case. , 2020, Hospital pediatrics.

[27]  L. Gostin,et al.  The Novel Coronavirus Originating in Wuhan, China: Challenges for Global Health Governance. , 2020, JAMA.

[28]  J. Antón,et al.  Epidemiological and clinical features of Kawasaki disease in Spain over 5 years and risk factors for aneurysm development. (2011-2016): KAWA-RACE study group , 2019, PloS one.

[29]  Evelyn P. Whitlock,et al.  Screening and Interventions for Childhood Overweight: A Summary of Evidence for the US Preventive Services Task Force , 2005, Pediatrics.